Bullous Pemphigoid

To demonstrate that dupilumab is superior to placebo in achieving sustained remission off oral corticosteroids (OCS) in patients with bullous pemphigoid (BP)

Inclusion Criteria

• Patients must have clinical features of BP (eg, urticarial or eczematous or erythematous plaques, bullae, pruritus) at the screening and baseline visits.
• Study participants are required to have histological and serological confirmation of BP by the baseline visit
• Bullous Pemphigoid Disease Area Index (BPDAI) activity score ≥24 at baseline and screening visits.

Exclusion Criteria

• Forms of pemphigoid other than classic BP (eg, mucous membrane-dominant BP, Brunsting-Perry cicatrial pemphigoid, anti-p200 pemphigoid, epidermolysis bullosa acquisita, or BP with concomitant pemphigus vulgaris)
• Patients who are receiving treatments known to cause or exacerbate BP (eg, angiotensin converting enzyme inhibitors, penicillamine, furosemide, phenacetin, dipeptidyl peptidase 4 inhibitor) who have not been on a stable dose of these medications for at least 4 weeks prior to the screening visit
• Have ever received treatment with an IL-4 or IL-13 antagonist such as dupilumab, tralokinumab, or lebrikizumab
  

Study Requirements

The study consists of a 2-week screening period, a 36-week double-blind treatment period, and a 12-week follow-up period.  There will be approximately 24 visits conducted throughout the trial.